Fulvestrant (Faslodex) for advanced or metastatic, hormone-receptor positive breast cancer – first line
NIHR HSRIC
Record ID 32016000396
English
Authors' objectives:
Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age, however it can affect younger women, and in rare cases, men as well.
There are many types of breast cancer. Fulvestrant is a new treatment for a type of breast cancer that is hormone-receptor positive and that has spread locally or to other parts of the body. Fulvestrant is given as an injection into the muscle. Studies at the moment are aiming to show how well it works and that it is safe to use for patients with hormone positive breast cancer.
If fulvestrant is licensed for use in the UK, it will offer a new treatment option for this patient group.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/fulvestrant-faslodex-for-advanced-or-metastatic-hormone-receptor-positive-breast-cancer-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Breast Neoplasms
- Estradiol
- Fulvestrant
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.